Proprotein Convertase 9

A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.

Also Known As:

Networked: 927 relevant articles (50 outcomes, 131 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Li, Jian-Jun: 19 articles (01/2022 - 06/2014)
2.	Fazio, Sergio: 15 articles (06/2022 - 12/2011)
3.	Xu, Rui-Xia: 14 articles (01/2022 - 06/2014)
4.	Seidah, Nabil G: 14 articles (01/2021 - 06/2003)
5.	Guo, Yuan-Lin: 13 articles (01/2022 - 06/2014)
6.	Zhu, Cheng-Gang: 13 articles (01/2022 - 06/2014)
7.	Sabatine, Marc S: 13 articles (12/2021 - 08/2013)
8.	Hovingh, G Kees: 12 articles (01/2021 - 03/2015)
9.	Ferri, Nicola: 11 articles (10/2022 - 01/2012)
10.	Wu, Na-Qiong: 11 articles (01/2022 - 06/2014)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2022 - "Clinical trials have demonstrated efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing risk of cardiovascular disease events, but effectiveness in routine clinical care has not been well-studied. " 03/20/2023 - "The clinical efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing major cardiovascular adverse events related to atherosclerotic cardiovascular disease (ASCVD) has been well established in recent large randomized outcome trials. " 01/01/2019 - "Correction to: Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition: A Genome-Wide Association Study and Mendelian Randomization Study in the HUNT, Norway." 01/01/2019 - "Although short-term trials have suggested that PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors are safe and reduce risk of cardiovascular diseases, their long-term safety is unclear. " 11/06/2018 - "Background The FOURIER (Further Cardiovascular Outcomes Research With PCSK9i [Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors] in Subjects With Elevated Risk) trial found a reduction in cardiovascular events in patients with atherosclerotic cardiovascular disease ( ASCVD ). "
2.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 10/19/2023 - "Limited data have been reported on the use of proprotein convertase subtilisin/kexin type 9 (PCSK 9) inhibitors during pregnancy in women with familial hypercholesterolemia (FH). " 02/01/2023 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9), a gene mainly related to familial hypercholesterolemia, was discovered in 2003. " 06/01/2022 - "Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. " 01/01/2022 - "A novel loop-mediated isothermal amplification-based genotyping method and its application for identifying proprotein convertase subtilisin/kexin type 9 variants in familial hypercholesterolemia." 11/29/2021 - "Our aim was to evaluate the role of NLR on pulse wave velocity (PWV) after adding-on proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9-i) in familial hypercholesterolemia (FH) subjects with ASCVD. "
3.	Hypercholesterolemia 01/01/2018 - "The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new treatment option for patients with hypercholesterolemia. " 01/15/2017 - "The role of proprotein convertase subtilisin/kexin type 9 inhibitors is unclear, but initial studies suggest a decrease in the rate of acute ASCVD events in patients with hypercholesterolemia." 11/01/2023 - "Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a breakthrough in the treatment of hypercholesterolemia. " 01/01/2022 - "In this chapter, we detail an efficient and increasingly used method to induce hypercholesterolemia in mice through adeno-associated virus-mediated transfer of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene." 01/01/2021 - "Adenovirus associated virus-proprotein convertase subtilisin/kexin type 9 (AAV-PCSK9) was used to induce hypercholesterolemia in the mice. "
4.	Dyslipidemias (Dyslipidemia) 06/06/2022 - "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients." 01/01/2022 - "Proprotein convertase subtilisin/kexin type 9 inhibitors: a turning point in HIV-associated dyslipidemia?" 09/01/2020 - "The use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has changed the clinical practice of dyslipidemia and their effects in cardiovascular events. " 01/01/2020 - "Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor was approved as an effective therapeutic drug for dyslipidemia patients. " 06/01/2019 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9)-related discoveries of the turn of the century have translated into substantial novelty in dyslipidemia treatment in the last 5 years. "
5.	Atherosclerosis 10/01/2021 - "However, although the previous studies showed that the beneficial impact of BBR on atherosclerosis might be associated with proprotein convertase subtilisin/kexin type 9 (PCSK9), the exact underlying mechanism are not fully determined. " 04/19/2020 - "The purpose of this study was to investigate whether aerobic exercise training inhibits atherosclerosis via the reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) expression in balloon-induced common carotid arteries of a high-fat-diet rats. " 12/01/2019 - "In this study, we assessed the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in T cell programming and atherogenesis. " 08/01/2017 - "The present study aimed to explore the direct toxicity of proprotein convertase subtilisin/kexin type 9 (PCSK9) to atherosclerosis (AS) and its association with apoptotic endothelial cells. " 07/01/2023 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has been demonstrated to exert a great cardioprotection in cardiometabolic impairments, including atherosclerosis. "

Related Drugs and Biologics

1.	Lipids
2.	LDL Cholesterol
3.	oxidized low density lipoprotein
4.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
5.	Monoclonal Antibodies
6.	Cholesterol
7.	evolocumab
8.	LDL Receptors (LDL Receptor)
9.	PCSK9 Inhibitors
10.	Ezetimibe (Zetia)

Related Therapies and Procedures

1.	Therapeutics
2.	Blood Component Removal (Apheresis)
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
5.	Thrombectomy